By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex reported after the close of the market on Monday that revenues for its fourth quarter increased 8 percent, helped by a 49 percent increase in consumables-related revenues.

For the three months ended Dec. 31, 2010 total revenues for the Austin, Texas-based molecular diagnostics and multiplex instrument firm rose to $41.2 million, compared to $38.2 million a year ago. It beat consensus Wall Street estimates of $38.1 million in revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.